On October 10, 2018 Incyte (Nasdaq: INCY) has reported that the Phase 2 intermediate data of its selective inhibitor of FGFR1 / 2/3 in the clinical research phase, pemigatinib (INCB54828), will be will present at the next European Congress of Oncology (ESMO) (Free ESMO Whitepaper) 2018 that will take place in Munich, Germany, from October 19 to 23, 2018 (Press release, Incyte, OCT 10, 2018, View Source [SID1234529846]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The information that will be announced in ESMO (Free ESMO Whitepaper) 2018 includes poster presentations on the FIGHT-202 study of pemigatinib in patients with advanced cholangiocarcinoma (cancer of the bile duct) and previously treated / metastatic or surgically unresectable with a genetic alteration of the factor of fibroblastic growth (FGF) / FGFR, as well as the FIGHT-201 study of pemigatinib in patients with metastatic or surgically unresectable urothelial carcinoma (cancer of the bladder) carrying an alteration of the FGF / FGFR gene.
"We are pleased that pemigatinib data – part of our portfolio of targeted treatments – have been selected for presentation at this year’s ESMO (Free ESMO Whitepaper) conference," said Steven Stein, MD, medical director, Incyte. "We are keen to share the latest intermediate data from the ongoing FIGHT-202 trial for pemigatinib in patients with cholangiocarcinoma, who continue to support our project to submit the new drug registration request in 2019 for this indication, as well as updated data from the FIGHT-201 study of pemigatinib in patients with urothelial carcinoma, which supports the recruitment for the continuous administration cohort of this trial ».
The summaries were made public today on the ESMO (Free ESMO Whitepaper) congress website, at View Source .
Poster details:
Intermediate results of FIGHT-202, an open and multicenter Phase 2 study of INCB054828 in patients (pts) with advanced and previously treated / metastatic or surgically unresectable cholangiocarcinoma (CCA) with / without alterations of the fibroblast growth factor (FGF) gene / FGF receptor (FGFR) (summary No. 756P, poster presentation session)
Sunday, October 21, 2018 from 12:45 pm Spanish Peninsular Time until 1:45 pm Spanish Peninsular Time (6:45 am East Coast Time at 7:45 am Eastern Time) in the Pavilion A3 – Poster Area Networking Hub
Intermediate results of FIGHT-202, an open-label multicentre study in Phase 2 of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) carrying the genetic alterations (GA) of fibroblast growth factor (FGF) / FGF receptor (FGFR) (summary No. 900P, poster presentation session)
Monday, October 22, 2018 from 12:45 pm Spanish Peninsular Time at 1:45 pm Spanish Peninsular Time (6:45 am East Coast Time at 7:45 am Eastern Time) in Hall A3 – Poster Area Networking Hub
The details of the full session and the data submission lists for ESMO (Free ESMO Whitepaper) 2018 can be found at:
About the FGFR and Pemigatinib (INCB54828)
Fibroblast growth factor receptors (FGFR) play an important role in the proliferation of tumor cells and in survival, migration and angiogenesis (formation of new blood vessels). The mutations, translocations and activating gene amplifications of the FGFRs are closely correlated with the development of various types of cancer.
Pemigatinib is a potent selective inhibitor of isoforms 1, 2 and 3 of FGFR that, in preclinical studies, has shown a selective pharmacological activity against cancer cells with alterations in FGFR. Phase 2 studies investigating the safety and efficacy of pemigatinib monotherapy for various neoplasms due to FGFR are underway. The FIGHT clinical trial program (FIbroblast Growth factor receptor in oncology and Hematology Trials) currently comprises the FIGHT-201 study in patients with metastatic or surgically unresectable bladder cancer, including activating alterations of FGFR3; the FIGHT-202 study in patients with metastatic or surgically unresectable cholangiocarcinoma who did not respond to previous treatment, including activating translocations of FGFR2; and the FIGHT-203 study in patients with myeloproliferative neoplasms with activating translocations of FGFR1.